8-K: GoodRx Reports Q4, Full Year 2025 Results; Pharma Direct Soars

GoodRx Holdings, Inc. announced its fourth quarter and full year 2025 financial results, with revenue and Adjusted EBITDA in line with guidance, driven by strong Pharma Direct growth.

Summary

• Full Year 2025 revenue increased 1% to $796.9 million, compared to $792.3 million in 2024.
• Full Year 2025 net income was $30.4 million, up from $16.4 million in 2024, with a net income margin of 3.8%.
• Full Year 2025 Adjusted EBITDA increased to $270.5 million, compared to $260.2 million in 2024, with an Adjusted EBITDA Margin of 33.9%.
• Pharma Direct revenue (formerly pharma manufacturer solutions) increased 41% year-over-year to $151.4 million for the full year 2025.
• Prescription transactions revenue decreased 6% to $544.0 million for the full year 2025, primarily due to a decrease in Monthly Active Consumers.
• Subscription revenue decreased 3% to $83.8 million for the full year 2025, driven by a decrease in the number of subscription plans.
• Net cash provided by operating activities for 2025 was $167.9 million, down from $183.9 million in 2024.
• The company repurchased 48.9 million shares of Class A common stock for an aggregate cost of $217.4 million in 2025, with $72.9 million remaining under the share repurchase program.
• Monthly Active Consumers declined from 6.6 million in Q4 2024 to 5.3 million in Q4 2025.
• Guidance for full year 2026 anticipates revenue between $750 million and $780 million, representing a 2% to 6% year-over-year decrease, and Adjusted EBITDA greater than $230 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed but strategically focused report. While core prescription and subscription metrics show declines, the strong growth in Pharma Direct and in-line financial performance against guidance provide a foundation for future strategic repositioning, albeit with anticipated revenue contraction in 2026.

Positives

• Full Year 2025 Revenue and Adjusted EBITDA results were in-line with previous guidance, demonstrating disciplined financial performance.
• Pharma Direct revenue exceeded previous outlook with over 40% year-over-year growth for 2025, reaching $151.4 million, positioning it as a key growth driver.
• Net income for FY 2025 significantly increased to $30.4 million from $16.4 million in 2024, indicating improved profitability.
• Adjusted EBITDA for FY 2025 increased to $270.5 million from $260.2 million in 2024, with margin expansion to 33.9%.
• The company repurchased $217.4 million of Class A common stock in 2025, demonstrating a commitment to shareholder returns and capital allocation discipline.
• Strong cash position with $261.8 million in cash and cash equivalents as of December 31, 2025.

Negatives

• Prescription transactions revenue decreased 6% to $544.0 million for FY 2025, primarily driven by a decrease in Monthly Active Consumers due to broader changes in the retail pharmacy landscape and volume reduction in an integrated savings program.
• Monthly Active Consumers declined from 6.6 million in Q4 2024 to 5.3 million in Q4 2025, indicating a reduction in the core user base for prescription transactions.
• Subscription revenue decreased 3% to $83.8 million for FY 2025, primarily driven by a decrease in the number of subscription plans.
• Net cash provided by operating activities decreased to $167.9 million in 2025 from $183.9 million in 2024.
• Guidance for full year 2026 anticipates a revenue decrease of 2% to 6% ($750 $780 million) compared to 2025 ($796.9 million), signaling near-term revenue contraction.

Risks

• Limited operating history and early stage of growth.
• Recent growth rates may not be sustainable or indicative of future growth.
• Ability to achieve broad market education and change consumer purchasing habits.
• General ability to continue to attract, acquire and retain consumers in a cost-effective manner.
• Significant reliance on prescription transactions offering and ability to expand offerings.
• Changes in medication pricing and the significant impact of pricing structures negotiated by industry participants.
• General inability to control the categories and types of prescriptions for which savings or discounted prices can be offered.
• Reliance on a limited number of industry participants, including pharmacy benefit managers, pharmacies, and pharma manufacturers.
• The competitive nature of the industry.
• Risks related to pandemics, epidemics, or outbreak of infectious disease.
• The accuracy of the estimate of the addressable market and other operational metrics.
• Ability to respond to changes in the market for prescription pricing and to maintain and expand the use of GoodRx codes.
• Ability to maintain positive perception of the platform or maintain and enhance the brand.
• Risks related to any failure to maintain effective internal control over financial reporting.
• Risks related to use of social media, emails, text messages, and other messaging channels as part of marketing strategy.
• Dependence on information technology systems and those of third-party vendors, and risks related to any failure or significant disruptions thereof.
• Risks related to government regulation of the internet, e-commerce, consumer data and privacy, information technology, and cybersecurity.
• Risks related to the use of AI and machine learning in the business.
• Risks related to a decrease in consumer willingness to receive correspondence or any technical, legal, or any other restrictions to send such correspondence.
• Risks related to any failure to comply with applicable data protection, privacy and security, advertising and consumer protection laws, regulations, standards, and other requirements.
• Ability to utilize net operating loss carryforwards and certain other tax attributes.
• The risk that the company may be unable to realize expected benefits from restructuring and cost reduction efforts.
• Ability to attract, develop, motivate and retain well-qualified employees.
• Risks related to acquisition strategy.
• Risks related to debt arrangements.
• Interruptions or delays in service on apps or websites or any undetected errors or design faults.
• Reliance on third-party platforms to distribute the platform and offerings, including software as-a-service technologies.
• Systems failures or other disruptions in the operations of these parties on which the company depends.
• Risks related to climate change.
• Risks associated with environmental sustainability and social initiatives.
• Risks related to intellectual property.
• Risks related to operating in the healthcare industry.
• Risks related to organizational structure.
• Litigation related risks.
• Ability to accurately forecast revenue and appropriately plan expenses in the future.
• Risks related to general economic factors, natural disasters, or other unexpected events.
• Risks related to fluctuations in tax obligations and effective income tax rate.
• Risks related to healthcare reform legislation and other proposed or future changes impacting the healthcare industry and healthcare spending, including the new platform TrumpRx.gov.

Future Outlook

Management anticipates full year 2026 revenue between $750 million and $780 million, representing a 2% to 6% year-over-year decrease. Adjusted EBITDA for 2026 is expected to be greater than $230 million. The company is focused on returning to growth beyond 2026, expanding its role in the healthcare ecosystem, and creating long-term value, with Pharma Direct positioned as a key growth driver. Priorities for 2026 include operating with rigor, preserving margin strength, and reinforcing the long-term durability of the platform.

Management Comments

• "We delivered a strong finish to the year by executing across our key priorities, expanding manufacturer partnerships, growing differentiated subscription offerings, and strengthening retail relationships." Wendy Barnes, President and Chief Executive Officer.
• "We rebranded Pharma Manufacturer Solutions as Pharma Direct and are continuing to elevate it as a key growth driver of our business, reflecting our belief that self-pay and direct-to-consumer engagement will define the future of prescription access." Wendy Barnes, President and Chief Executive Officer.
• "We are confident that the actions were taking today position us to return to growth beyond 2026, expand our role across the healthcare ecosystem, and create meaningful long-term value for consumers, partners, and stockholders." Wendy Barnes, President and Chief Executive Officer.
• "We closed the year with disciplined financial performance and delivered results in line with our latest guidance." Chris McGinnis, Chief Financial Officer and Treasurer.
• "Adjusted EBITDA finished just above the midpoint of our range, reflecting continued cost discipline and focused execution across the business." Chris McGinnis, Chief Financial Officer and Treasurer.
• "Pharma Direct grew 41% year-over-year, underscoring the strategic progress we are making as we reposition the Company." Chris McGinnis, Chief Financial Officer and Treasurer.
• "As we enter 2026, our priority is to operate with rigor, preserve margin strength, and reinforce the long-term durability of our platform." Chris McGinnis, Chief Financial Officer and Treasurer.

Industry Context

StockSavvy.ai notes that GoodRx's strategic pivot towards Pharma Direct aligns with broader industry trends emphasizing direct-to-consumer engagement and self-pay models in prescription access, potentially mitigating headwinds from traditional pharmacy channels and PBM complexities. The decline in Monthly Active Consumers and subscription plans reflects ongoing challenges in the retail pharmacy landscape, including store closures, which impact the core prescription transactions business. The mention of 'TrumpRx.gov' indicates potential future government intervention in the prescription market, adding a layer of regulatory uncertainty to the industry.

Stakeholder Impact

• Shareholders: Positive impact from share repurchases and disciplined capital allocation, but potential concern from declining core metrics and anticipated 2026 revenue decrease. Long-term value creation is a stated goal.
• Consumers: Continued access to medication savings through the platform, with new condition-specific and RxSmartSaver+ subscription programs launched.
• Partners (Pharma Manufacturers, Retail Pharmacies, PBMs): Expanding manufacturer partnerships and strengthening retail relationships are key priorities. Pharma Direct growth indicates deeper engagement with manufacturers.
• Employees: Restructuring and cost reduction efforts are mentioned as a risk, implying potential impact on employees, though no specific details are provided.

Next Steps

• Host an investor conference call and webcast on February 26, 2026, at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss results and business outlook.
• Continue to execute on key priorities: expanding manufacturer partnerships, growing differentiated subscription offerings, and strengthening retail relationships.
• Focus on operating with rigor, preserving margin strength, and reinforcing the long-term durability of the platform in 2026.
• Aim to return to growth beyond 2026.

Key Dates

Recommendation

GoodRx's Q4 and full-year 2025 results were largely in line with guidance, demonstrating disciplined financial management and strong growth in the Pharma Direct segment. However, the core prescription transactions and subscription businesses continue to face headwinds, reflected in declining Monthly Active Consumers and subscription plans. The 2026 revenue guidance projects a further decline, indicating ongoing challenges in the near term. While the strategic pivot to Pharma Direct is promising for long-term growth, the immediate outlook suggests a period of transition and potential revenue contraction. Investors should hold to observe the effectiveness of the strategic repositioning and the company's ability to return to overall growth beyond 2026, especially given the competitive landscape and evolving regulatory environment.

Keywords

GoodRx, GDRX, Q4 2025, Full Year 2025, financial results, earnings, prescription savings, Pharma Direct, healthcare technology, medication access, Adjusted EBITDA, revenue, net income, share repurchase, consumer health, digital health, pharmacy, PBM